SEC says insider made $10M on Abbott, CFR deal

Nonpublic information about Abbott's ($ABT) May agreement to buy CFR Pharmaceuticals helped score a former CFR board member a hefty profit, according to U.S. regulators. And they're charging him with insider trading.

On Monday, the SEC filed a civil lawsuit accusing former director Juan Cruz Bilbao Hormaeche of racking up more than $10.1 million through trades on private information he learned during board meetings that preceded the deal, Reuters reports. The lawsuit also charges a business associate of Bilbao's who allegedly processed transactions for Bilbao and himself, earning $500,000 in the process.

According to regulators, after learning of Abbott's offer in mid-March, Bilbao used his associate to buy up more than 700,000 American depository shares of CFR totaling $14.35 million in the name of a Virgin Islands entity, with the associate buying $700,000 worth of CFR shares of his own. After Abbott announced the acquisition and CFR's stock price rose, they tendered those shares to make a profit.

This isn't the first deal in a banner M&A year for pharma to produce insider trading charges. Back in October, for one, the SEC and federal prosecutors filed a civil and criminal complaint against a former Merck ($MRK) employee who they said used info from confidential files to have a friend make trades on future buyout target Idenix.

- get more from Reuters

Special Report: Pharma's top 10 M&A deals of 2014's first halfAbbott/CFR

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…